Savara Announces Expedited U.S. Molgradex Development Strategy

Ongoing IMPALA Study to be Expanded to Serve as Global Pivotal Study for Registration AUSTIN, Texas, May 10, 2017 -- (Healthcare Sales & Marketing Network) -- Savara Inc. (NASDAQ: SVRA) today announced that it has received guidance from the U.S. Food a... Biopharmaceuticals, FDA Savara, Molgradex, pulmonary alveolar proteinosis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news